Upcoming Discovery Events

Neuroscience Discovery Symposium

15 September 2022 |

Online: BST (UTC+1)

15 September 2022

Online: BST (UTC+1)

Emerging Technologies And Methodologies In Small Molecule Drug Discovery & Synthesis Symposium

27 - 29 September 2022 |

Toledo, Spain

27 - 29 September 2022

Toledo, Spain

A three-day event taking place in Toledo, Spain, to explore the latest advancements in organic synthesis, novel therapeutic modalities & approaches in medicinal chemistry, and new organic synthesis methodologies. Organised by Janssen Pharmaceuticals.

Discovery US: In-Person

17 - 18 November 2022 |

Boston, USA

17 - 18 November 2022

Boston, USA

200+ leaders, experts and scientists helping to shape the future of drug discovery and development

Automation in Discovery Symposium

February 2023 |


February 2023


More Information Coming Soon

Upcoming Discussion Groups

Our monthly Discussion Groups are hosted by a panel of leading industry experts who explore some of the key issues facing Drug Discovery, Computational & Molecular Drug Design, as well as Medicinal Chemistry today.

Attendance to our Discussion Groups is available to members of our Discovery Member Community. For more information about Membership, please click here.

Novel Technologies & AI Applied to Drug Design

Taking place Tuesday 20 September | 15:00 (UTC+1)

Discussion Leader

  • Uli Schmitz, Executive Director, Structural Chemistry at Gilead Sciences
  • Robert Soliva, Head of Drug Discovery, Oryzon Genomics


  • Bringing 3D structural information into the AI/ML optimisation cycle
  • Machine learning in DEL screening follow up
  • AI generative methods for compound optimisation vs. exhaustive enumeration
  • Is ML working for physical chemical properties?
  • Contribution of ML methods for HTS hit deconvolution
Automation and Synthesis in Organic Chemistry

Taking place 20 October 2022 | 15:00 (UTC+1)

Discussion leaders:

  • Nicole Harriott, Executive Director, Neurocrine
  • Derrick Miyao, Manager of Automation, Neurocrine

Discussion topics:

  • Custom software generation
  • How far should you automate? Fit-for-purpose or full automation?
  • AI/ML techniques
Genomic & CRISPR Techniques to Accelerate Target Discovery

Monday 21 November 2022 | 15:00 (UTC)

Discussion Group Leaders:

  • Benedict Cross, Chief Technology Officer, Phoremost
  • Helen Yu, Senior Director of Biology, Gilead


  • Evolution of CRISPR-based target discovery
  • Successes in using genomics tools to accelerate discovery
  • Challenges and current limitations of CRISPR technology
  • Single celled approaches and complex biology
  • Alternative solutions and next-generation technologies

Reports and write-ups pertaining to previous Discussion Groups are available in our In-Depths section.

Previous Discussion Groups

Discussion Group Leaders:

  • Ianai Fishbein, Director of Pharmacology, Teva Pharma
  • Martin Joseph Dudziak, Director of Research Programs, TETRAD Inst.

Discussion Topics:

  • With so much understanding about neuroscience mechanisms, why are there so few effective treatments?
  • Incorrect targets or incorrect target engagement?
  • Strategies for treatment
  • Challenges with transferring from academia to industry
  • Dysautonomia Disorders
  • Autoimmune Diseases
  • PASC Long COVID – Neurological After Effects
  • Population Health Equity

Discussion Group Leaders:

  • Simon Bushell, Head of Structural Biology at Orbit Discovery

Discussion Topics:

  • Working with the constraints of your platform
  • Marketability of targets
  • The rise of Artificial Intelligence and Machine Learning

April 2022

Discussion Group Leaders:

  • Markus Schade, Senior Scientist at AstraZeneca
  • Thomas Hayhow, Associate Principal Scientist at AstraZeneca

Discussion Topics: Innovation in PROTACS 

  • Discovery and profiling of AZ’6421 an oral ERα-PROTAC with an in vitro-in vivo disconnect
  • Preclinical Oral PROTACS
  • New PROTAC targets
  • Targeting Drug-Resistant Mutants & Beyond Catalytic Activity
April 2022

Discussion Group Leader:

  • Govinda Rao Bhisetti, Principal Investigator, Head of Computational Chemistry, Biogen

Discussion Topics:

  • The Use of Alpha-Fold, Something Useful Or Complete Hype?
  • How can we optimise the use?
  • Current status of use and limitations
  • Difficulties in generation of structures
  • Potential in improved use of Alpha-Fold


March 2022

Discussion Group Leaders:

Thierry Lavé, Head of Project Leaders and Modelling, Roche

Nikolche Gjorevski, Principal Scientist and Lead, Roche Institute for Translational Bioengineering, F. Hoffmann-La Roche Ltd


Thierry Lavé: Exploring the impact of virtual patient on discovery and development

Discussion Topics:

  • Next Generation Organoids
  • Patient Derived Organoids
  • Translatability
  • Organ on Chip

February 2022

Discussion Group Leaders:

Joe Franklin (VP Chemistry, Anagenex)
Paul Richardson, (Director, Discovery Chemistry, Pfizer)


 Joe Franklin: Traditional DEL & DEL with Machine Learning
• How to use ML to find HITS
• How Anagenex use ML

Panel Discussion: Challenges of DEL and Hit Finding 

  • Machine Learning & DNA Encoded Libraries
  • Challenges – and where do we go next
  • Deconvolution of the hits
  • Biophysical vs Biochemical Interrogation of HITS – Which should come first?
  • Why hasn’t del been more successful getting molecules to the clinic?

December 2021

This month’s discussion group focuses on novel methods for protein degradation and moving forward from the traditionally used E3 Ligases. Join our December discussion group to join the conversation with industry leaders and pioneers, learn about the latest market trends and developments, and explore the future of targeted protein degradation.

Panel Discussion

Drug Discovery – Modalities and New Mechanisms

–       New modalities e.g. Triple modalities

–       Novel E3 ligases development

–       Molecular glues update – moving towards rational design

Discussion Group Leader: Markus Schade, Senior Scientist, AstraZeneca


  • Joanne Wayne, Senior Scientist, Vernalis
  • Benedict Cross, Chief Technology Officer, Phoremost
  • Gustavo J. Gutierrez, Principal Scientist, Galapagos
  • Zhenyi (Jason) Hu, Postdoctoral Associate, Crews lab, Yale University
  • Magnus Walter, Head of Discovery Chemistry, Screening Biology & Operations, AbbVie

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Member Community Login